Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
Authors:
- Bram De LaereBLBram De Laere
- Johan LindbergJLJohan Lindberg
- for the CORE-ARV-CTC and ProBIO InvestigatorsFIfor the CORE-ARV-CTC and ProBIO Investigators
- 1 July 2019
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (7) , 1060-1062
Abstract
This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TKeywords
This publication has 6 references indexed in Scilit:
- TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2019
- Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate CancerJAMA Oncology, 2018
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerCancer Discovery, 2018
- Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression PatternsEuropean Urology, 2017
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and EnzalutamideJournal of Clinical Oncology, 2017
- Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker studyAnnals of Oncology, 2017